Lorenzo Somaini Selected Research

Type 2 Diabetes Mellitus (MODY)

10/2020	Further evidence for the involvement of the PPARγ system on alcohol intake and sensitivity in rodents.
8/2013	Activation of PPARγ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats.
4/2011	Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lorenzo Somaini Research Topics

Disease

6	Alcoholism (Alcohol Abuse) 03/2023 - 04/2011
6	Opioid-Related Disorders (Opiate Addiction) 10/2021 - 01/2016
3	Type 2 Diabetes Mellitus (MODY) 10/2020 - 04/2011
3	Infections 01/2019 - 12/2017
3	Substance-Related Disorders (Drug Abuse) 01/2017 - 04/2009
2	Mood Disorders (Mood Disorder) 01/2017 - 11/2016
2	Heroin Dependence (Heroin Abuse) 01/2016 - 09/2011
2	Insulin Resistance 08/2013 - 04/2011
2	Anxiety Disorders (Anxiety Disorder) 07/2013 - 03/2012
2	Neuralgia (Stump Neuralgia) 07/2013 - 03/2012
2	Cocaine-Related Disorders (Cocaine Addiction) 07/2013 - 05/2011
2	Partial Epilepsies (Epilepsy, Partial) 07/2013 - 03/2012
1	Depressive Disorder (Melancholia) 11/2023
1	Mental Disorders (Mental Disorder) 01/2023
1	Reinfection 01/2023
1	Binge Drinking 10/2020
1	Liver Diseases (Liver Disease) 01/2019
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2017
1	Tobacco Use Disorder (Nicotine Dependence) 11/2016
1	Erectile Dysfunction 01/2016
1	Narcolepsy 11/2015
1	Neuroinflammatory Diseases 06/2015
1	Nausea 01/2010
1	Multiple Sclerosis 01/2010
1	Glaucoma 01/2010
1	Central Nervous System Diseases (CNS Diseases) 01/2010
1	Vomiting 01/2010

Drug/Important Bio-Agent (IBA)

8	Opioid Analgesics (Opioids)IBA 11/2023 - 01/2016
5	Buprenorphine (Subutex)FDA LinkGeneric 10/2021 - 09/2011
4	Methadone (Dolophine)FDA LinkGeneric 12/2017 - 09/2011
3	Pioglitazone (Actos)FDA Link 10/2020 - 04/2011
2	AcidsIBA 01/2023 - 11/2015
2	Opioid Receptors (Opioid Receptor)IBA 01/2020 - 01/2016
2	Heroin (Diamorphine)IBA 01/2017 - 01/2016
2	Dronabinol (THC)FDA LinkGeneric 06/2015 - 01/2010
2	Pregabalin (Lyrica)FDA Link 07/2013 - 03/2012
2	gamma-Aminobutyric Acid (GABA)IBA 07/2013 - 03/2012
2	Aminobutyrates (Aminobutyric Acid)IBA 07/2013 - 03/2012
1	Sodium Oxybate (gamma Hydroxybutyrate)FDA Link 03/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2023
1	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2017
1	Hormones (Hormone)IBA 01/2017
1	Oxytocin (Pitocin)FDA LinkGeneric 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Hydrocortisone (Cortisol)FDA LinkGeneric 11/2016
1	N-(2-acetamido)-2-aminoethanesulfonic acid (ACES)IBA 11/2016
1	Adrenocorticotropic Hormone (ACTH)FDA Link 11/2016
1	ProlactinIBA 01/2016
1	CytokinesIBA 06/2015
1	Interleukin-10 (Interleukin 10)IBA 06/2015
1	Glucose (Dextrose)FDA LinkGeneric 03/2015
1	Naltrexone (ReVia)FDA LinkGeneric 08/2013
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 08/2013
1	Naloxone (Narcan)FDA LinkGeneric 09/2011
1	Naloxone Drug Combination Buprenorphine FDA Link 09/2011
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2011
1	Dopamine Receptors (Dopamine Receptor)IBA 05/2011
1	AntioxidantsIBA 04/2011
1	nabilone (Cesamet)FDA Link 01/2010
1	nabiximols (Sativex)IBA 01/2010
1	CannabinoidsIBA 01/2010

Therapy/Procedure

5	Therapeutics 10/2021 - 04/2009
3	Drug Therapy (Chemotherapy) 12/2017 - 01/2010
2	Opiate Substitution Treatment 01/2016 - 01/2016
1	Duration of Therapy 03/2023
1	Drug Prescriptions 01/2023